SCHEMBL4092367

SCHEMBL4092367

CC(C)(C)c1ccc(-c2nc(N3CCCCC3)c3ccccc3n2)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.78
MEN1 O00255 3/20 0.78
RAB9A P51151 2/20 0.78
TP53 P04637 5/20 0.76
ACP1 P24666 2/20 0.75
LMNA P02545 4/20 0.68
MAPT P10636 3/20 0.68
TSHR P16473 5/20 0.66
USP2 O75604 2/20 0.66
GBA1 P04062 1/20 0.65
MAPK1 P28482 4/20 0.60
ALDH1A1 P00352 3/20 0.60
HSD17B10 Q99714 2/20 0.60
NPSR1 Q6W5P4 1/20 0.60
ABCG2 Q9UNQ0 1/20 0.58
METAP1 P53582 1/20 0.56
HIF1A Q16665 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
KDM4E B2RXH2 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4096150 0.99 MEN1 (0.80) KMT2AMEN1RAB9ATP53ACP1
SCHEMBL4089287 0.89 RAB9A (0.98) KMT2AMEN1RAB9ATP53ACP1
SCHEMBL4089879 0.88 MEN1 (0.74) KMT2AMEN1RAB9ATP53ACP1
SCHEMBL4088943 0.88 MEN1 (0.74) KMT2AMEN1RAB9ATP53ACP1
SCHEMBL4090807 0.87 ACP1 (0.75) KMT2AMEN1RAB9ATP53ACP1
SCHEMBL1083859 0.86 ACP1 (1.00) KMT2AMEN1RAB9ATP53ACP1
SCHEMBL1084122 0.86 ACP1 (1.00) KMT2AMEN1RAB9ATP53ACP1
SCHEMBL4095137 0.86 ACP1 (0.74) KMT2AMEN1RAB9ATP53ACP1
SCHEMBL4089260 0.85 ACP1 (1.00) KMT2AMEN1RAB9ATP53ACP1
SCHEMBL4094693 0.83 MEN1 (0.72) KMT2AMEN1RAB9ATP53ACP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 KMT2A 1424/4885MEN1 718/4885RAB9A 640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.